Daniele Focosi to Immunization, Passive
This is a "connection" page, showing publications Daniele Focosi has written about Immunization, Passive.
Connection Strength
0.826
-
COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses. 2021 08 11; 13(8).
Score: 0.071
-
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opin Drug Discov. 2021 12; 16(12):1403-1414.
Score: 0.071
-
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses. 2021 06 23; 13(7).
Score: 0.071
-
Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. Eur J Haematol. 2021 Jul; 107(1):24-28.
Score: 0.070
-
Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect. 2021 Jul; 27(7):987-992.
Score: 0.070
-
COVID-19 convalescent plasma therapy: hit fast, hit hard! Vox Sang. 2021 10; 116(9):935-942.
Score: 0.070
-
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. 2021 11; 31(6):e2231.
Score: 0.069
-
Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. Transfus Clin Biol. 2021 May; 28(2):132-134.
Score: 0.069
-
The art of the possible in approaching efficacy trials for COVID19 convalescent plasma. Int J Infect Dis. 2021 Jan; 102:244-246.
Score: 0.068
-
What is the optimal usage of coronavirus disease 2019 convalescent plasma donations? Clin Microbiol Infect. 2021 Feb; 27(2):163-165.
Score: 0.067
-
Convalescent Plasma Therapy for COVID-19: State of the Art. Clin Microbiol Rev. 2020 09 16; 33(4).
Score: 0.067
-
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs. 2020 Jan-Dec; 12(1):1854149.
Score: 0.064